Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

41.22 1.12 +2.79%
Market cap
$6.7B
P/E
102×
Fwd P/E
−108×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
19.03 12.90 13.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
7 7 8 4 5 5 5 7 5 5
P/S ratio
3.12 3.05 2.86 3.81 3.19 3.05 2.74 4.18 9.38 11.40
Altman Z-Score
5.33 6.16 4.04 2.52 2.49 1.84 2.31 4.14 8.24 9.44
P/FCF ratio
9.57 11.71 13.45 0.00 50.60 76.77 0.00 150.78 0.00 0.00
Altman Z″-Score (non-manufacturers)
6.24 5.46 3.57 0.46 1.04 0.65 0.51 1.71 1.57 2.05
Beneish M-Score
(3.29) (2.19) (2.10) (2.73) (2.32) (2.87) (3.31) (3.01) (2.77) (2.77)
P/Operating CF
27.10 24.98 44.36 4,045.85 120.68 47.04 76.16 75.64 235.92 1,124.40
P/B ratio
2.53 3.25 3.96 4.06 3.36 2.97 2.95 3.91 7.04 7.03
Price to Tangible BV
2.66 3.44 4.26 4.59 3.96 3.67 3.81 5.16 9.92 10.64
EV/Sales
2.42 2.76 2.57 3.53 2.98 2.70 2.52 3.95 9.21 11.11
EV/EBITDA
12.73 9.56 8.74 54.63 19.86 0.00 0.00 952.62 0.00 0.00
EV/Operating CF
6.87 9.78 10.65 186.31 34.44 33.90 40.87 43.49 433.53 (129.85)
EV/FCF
7.43 10.57 12.09 (227.81) 47.35 68.05 (163.99) 142.22 (260.41) (77.24)
Quick Ratio
3.04 2.44 2.13 1.80 1.80 2.08 2.03 2.45 2.29 3.25
Current Ratio
3.55 3.04 2.86 2.27 2.25 2.54 2.46 2.89 2.78 3.73
Net Debt/EBITDA
(4.69) (1.67) (0.99) (4.39) (1.36) 11.78 2.71 (57.37) 3.08 1.87
Debt/Assets
0.00% 0.00% 13.61% 14.93% 14.61% 14.10% 15.35% 15.30% 15.66% 16.43%
Debt/Equity
0.00 0.00 0.24 0.28 0.27 0.26 0.26 0.24 0.23 0.23
Asset Turnover
0.65 0.74 0.81 0.56 0.59 0.55 0.65 0.60 0.51 0.42
Operating CF/Net income
2.15 1.20 1.13 (0.13) (2.11) (0.75) (0.37) (0.71) (0.12) 0.31
Capex/Depreciation
(1.45) (1.16) (0.64) (0.49) (0.37) (0.51) (1.12) (0.66) (0.52) (0.46)
Interest Coverage
20.69 18.63 17.98 (0.47) 8.71 (12.98) (12.90) (6.42) (12.32) (14.01)
ROE
14.72% 27.52% 31.67% (14.68%) (4.42%) (10.30%) (17.43%) (11.74%) (13.10%) (16.52%)
ROA
10.64% 17.51% 17.35% (7.94%) (2.42%) (5.90%) (10.83%) (7.69%) (8.96%) (11.64%)
ROIC
31.75% 36.86% 35.95% (0.52%) 7.01% (9.94%) (13.25%) (6.80%) (8.80%) (13.10%)
Return on Tangible Assets
15.03% 31.17% 29.84% (18.50%) (5.17%) (10.84%) (21.07%) (14.61%) (19.68%) (24.71%)
Average Days of Receivables
82.61 90.11 72.96 94.54 97.39 96.68 80.14 97.47 94.38 93.54
Research and Development Expense of Revenue
21.95% 15.75% 16.28% 24.53% 24.79% 37.99% 43.80% 38.88% 45.71% 51.92%
Selling, General and Administrative Expense of Revenue
47.53% 41.42% 41.47% 53.13% 46.83% 51.87% 51.19% 48.11% 46.67% 50.17%
Intangible Assets out of Total Assets
0.03 0.04 0.04 0.06 0.08 0.10 0.13 0.16 0.19 0.24
Share Based Compensation of Revenue
6.69% 6.20% 6.07% 8.48% 7.47% 8.68% 8.62% 9.63% 9.29% 12.66%
Graham Net Nets
0.27 0.17 0.12 0.05 0.04 0.07 0.08 0.07 0.03 0.03
Graham Number
19.11 21.08 18.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
5.25% 7.75% 7.51% (3.71%) (1.29%) (3.51%) (6.18%) (3.02%) (1.87%) (2.44%)
Free Cash Flow Yield
10.45% 8.54% 7.43% (0.41%) 1.98% 1.30% (0.56%) 0.66% (0.38%) (1.26%)
Revenue per Share
8.96 9.42 10.01 6.79 7.29 6.54 7.46 7.05 5.89 4.92
Operating CF per Share
3.16 2.66 2.41 0.13 0.63 0.52 0.46 0.64 0.13 (0.42)
Capex per Share
(0.24) (0.20) (0.29) (0.23) (0.18) (0.26) (0.57) (0.44) (0.33) (0.29)
Free Cash Flow per Share
2.92 2.46 2.13 (0.11) 0.45 0.26 (0.11) 0.20 (0.21) (0.71)
Cash per Share
8.01 4.54 4.65 3.72 3.33 4.00 3.41 3.48 2.83 3.28
Shareholders Equity per Share
11.05 8.86 7.24 6.37 6.91 6.72 6.91 7.55 7.84 7.98
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
11.05 8.86 7.24 6.37 6.91 6.72 6.91 7.55 7.84 7.98
Free Cash Flow
481.42 406.10 353.66 (17.21) 72.98 41.27 (17.96) 30.36 (31.95) (107.26)
Working Capital
1,385.72 950.16 965.29 632.56 590.88 672.71 570.86 643.48 517.72 578.69
Capital Expenditures
(39.33) (33.02) (47.69) (38.25) (28.73) (41.58) (90.04) (68.92) (51.14) (43.46)
Net Current Asset Value
1,261.46 824.77 551.97 210.08 150.27 228.22 242.01 329.53 214.43 273.74
EV/EBIT
14.09 10.21 10.32 0.00 35.84 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.03 0.02 0.03 0.03 0.02 0.04 0.08 0.06 0.06 0.06
Price to Operating Income
18.15 11.31 11.49 0.00 38.30 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.12 0.13 0.33 0.35 0.23 0.23 0.22 0.33 0.35 0.36
Cash ROIC
15.34% 18.32% 15.60% (0.88%) 3.75% 2.09% (0.95%) 1.53% (1.67%) (5.39%)
Accounts Receivable Turnover
4.11 4.34 5.36 3.70 3.99 3.90 4.26 4.16 4.25 4.30
Accounts Payable Turnover
0.83 1.15 1.10 1.02 0.64 0.45 0.51 0.57 0.63 0.70
Inventory Turnover
1.04 1.33 1.38 1.31 1.43 1.57 1.88 1.92 1.98 2.61
Average Days of Payables
537.99 275.73 347.00 368.38 385.66 843.68 754.82 690.53 674.97 572.01
Days of Inventory on Hand
365.31 272.10 268.89 303.66 278.08 257.38 205.99 186.61 220.01 174.04
Average Receivables
359.28 358.50 310.22 300.58 294.17 266.11 274.65 262.91 212.35 173.29
Average Payables
237.45 212.95 230.33 214.29 310.33 392.60 353.40 309.96 246.61 187.90
Average Inventory
189.76 184.65 183.91 165.88 138.04 113.77 96.00 91.74 78.14 50.70
Average Assets
2,271.28 2,095.90 2,050.10 1,994.23 1,987.11 1,877.57 1,815.21 1,811.12 1,761.83 1,791.08
Average Common Equity
1,642.14 1,333.83 1,123.22 1,078.17 1,089.78 1,076.21 1,128.36 1,187.05 1,206.14 1,261.88

Fold the line items

Columns are period end dates